Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy and safety of KPS-0373 in patients with SCD.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01004016
Study type Interventional
Source Kissei Pharmaceutical Co., Ltd.
Contact
Status Completed
Phase Phase 2

See also
  Status Clinical Trial Phase
Completed NCT01970098 - A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3
Completed NCT02889302 - An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3
Completed NCT04107740 - C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration Phase 4
Completed NCT00863538 - Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 2
Completed NCT01970124 - A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3
Completed NCT01970111 - An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3
Completed NCT01970137 - A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3